The COVID-19 pandemic has highlighted the urgent need for antiviral agents, generating significant interest in related research. Tagesspiegel.de hits this spot by discussing the MucBoost research project, involving multiple partners and focusing on our new antiviral mechanism of action in a thorough article. With its extensive reach of 9.2 million unique users per month, tagesspiegel.de … Read more
Learn more about the science behind our nasal spray in this video. The YouTube channel “Breaking Lab” presents the team MucBoost and other teams of the challenge “broad-spectrum antivirals”, which was launched by SPRIND, the Federal Agency for Disruptive Innovation – Germany. The MucBoost project is one of the winners of the challenge’s second stage
The local newspaper “Der Teckbote” has an affectionate report about a son of the city Kirchheim unter Teck – Dr. Daniel Lauster. The founding of his research group at the Freie University of Berlin and his “unappetizing” research topics are reported in detail. As unappetizing – with a wink – they mention the general research … Read more
A detailed report on three winners of the challenge from SPRIND – the Federal Agency for Disruptive Innovation – Germany on the topic of “broad-spectrum antivirals” appears in the blog of the magazine “Laborjournal”. The first thing in the article is to introduce and explain Dr. Daniel Lauster and his research project at the Freie … Read more
The newspage of the German Pharmacist Association (Pharmazeutische-Zeitung.de) features the the first level of the challenge „broad-spectrum antivirals“ by SPRIND – the Federal Agency for Disruptive Innovation – Germany with an article. Among the nine teams is the MucBoost project, from which MucosaTec GmbH is a spin-off. Pharmazeutische-Zeitung.de counted 3,470,205 page impressions and 1,733,170 visits … Read more
© COPYRIGHT MUCOSATEC
